Mechanism of swertiamarin and novel nitrogen-containing metabolites (R)-Gentiandiol and (S)-Gentiandiol in treating non-alcoholic fatty liver disease in rats: an untargeted metabolomics study based on UPLC-Q-TOF/MS

Swertiamarin, a predominant iridoid glycoside from hepatoprotective Swertia herbs, is biotransformed <i>in vivo</i> into nitrogen-containing metabolites (<i>R</i>)-gentiandiol and (<i>S</i>)-gentiandiol. These metabolites may be the real active hepatoprotective agents. A high-fat diet-fed rat model was treated for 12 weeks with swertiamarin, (<i>R</i>)-gentiandiol, (<i>S</i>)-gentiandiol and silybin, and the therapeutic effects on non-alcoholic fatty liver disease (NAFLD) were systematically evaluated through biochemical indices and histopathological observations. Swertiamarin and (<i>R</i>)-gentiandiol reversed high-fat diet-induced metabolic disturbances, reduced serum alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, low-density lipoprotein cholesterol and malondialdehyde, while elevated high-density lipoprotein cholesterol, superoxide dismutase and glutathione peroxidase. However, (<i>S</i>)-gentiandiol exhibited no efficacy. The differential biomarkers in the serum of high-fat diet-fed rats were determined and identified by the metabolomics method combined with multivariate analysis. The results of enrichment analysis showed that NAFLD could be improved by swertiamarin and (<i>R</i>)-gentiandiol by regulating the levels of 21 biomarkers, such as stearic acid, palmitic acid and PC (36:3). According to the pathway enrichment results, swertiamarin and (<i>R</i>)-gentiandiol had potent combined effects in regulating taurine and hypotaurine metabolism, arachidonic acid metabolism, etc. This study is the first verification of the metabolite activity in the NAFLD model, and the dose-dependent effects of (<i>R</i>)-gentiandiol can be used to underscore its central role in swertiamarin's bioactivity. These findings offer valuable insights to clarify the pharmaceutical material for hepatoprotective effect of <i>Swertia</i> herbs.

Authors

Institutions

Publication Details

Journal
Frontiers in Pharmacology
Published
2025-09-22
DOI
https://doi.org/10.3389/fphar.2025.1655026
Primary Topic
Liver Disease Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Mechanism of swertiamarin and novel nitrogen-containing metabolites (R)-Gentiandiol and (S)-Gentiandiol in treating non-alcoholic fatty liver disease in rats: an untargeted metabolomics study based on UPLC-Q-TOF/MS

Minyue Zhang, Hailong Zhang, Xianna Li, Zhigang Wang et al.
Frontiers in Pharmacology
Liver Disease Diagnosis and Treatment
article

Mechanism of swertiamarin and novel nitrogen-containing metabolites (R)-Gentiandiol and (S)-Gentiandiol in treating non-alcoholic fatty liver disease in rats: an untargeted metabolomics study based on UPLC-Q-TOF/MS

Minyue Zhang, Hailong Zhang, Xianna Li, Zhigang Wang, Fuyan Cui, Shuhan Tang, Ying‐Ping Wang, Yidan Sun, Pengyu Li, Rong Ma, Hongying Xu, Xintong Li, Yingying Wang, Yaqi Xu, Hao Li
article en

Abstract

Swertiamarin, a predominant iridoid glycoside from hepatoprotective Swertia herbs, is biotransformed <i>in vivo</i> into nitrogen-containing metabolites (<i>R</i>)-gentiandiol and (<i>S</i>)-gentiandiol. These metabolites may be the real active hepatoprotective agents. A high-fat diet-fed rat model was treated for 12 weeks with swertiamarin, (<i>R</i>)-gentiandiol, (<i>S</i>)-gentiandiol and silybin, and the therapeutic effects on non-alcoholic fatty liver disease (NAFLD) were systematically evaluated through biochemical indices and histopathological observations. Swertiamarin and (<i>R</i>)-gentiandiol reversed high-fat diet-induced metabolic disturbances, reduced serum alanine aminotransferase, aspartate aminotransferase, total cholesterol, triglyceride, low-density lipoprotein cholesterol and malondialdehyde, while elevated high-density lipoprotein cholesterol, superoxide dismutase and glutathione peroxidase. However, (<i>S</i>)-gentiandiol exhibited no efficacy. The differential biomarkers in the serum of high-fat diet-fed rats were determined and identified by the metabolomics method combined with multivariate analysis. The results of enrichment analysis showed that NAFLD could be improved by swertiamarin and (<i>R</i>)-gentiandiol by regulating the levels of 21 biomarkers, such as stearic acid, palmitic acid and PC (36:3). According to the pathway enrichment results, swertiamarin and (<i>R</i>)-gentiandiol had potent combined effects in regulating taurine and hypotaurine metabolism, arachidonic acid metabolism, etc. This study is the first verification of the metabolite activity in the NAFLD model, and the dose-dependent effects of (<i>R</i>)-gentiandiol can be used to underscore its central role in swertiamarin's bioactivity. These findings offer valuable insights to clarify the pharmaceutical material for hepatoprotective effect of <i>Swertia</i> herbs.

Frontiers in PharmacologyVol. 16
Harbin Medical University (CN), Heilongjiang University of Chinese Medicine (CN), Third Affiliated Hospital of Harbin Medical University (CN), Shangqiu First People's Hospital (CN), University of Toyama (JP), Xi'an Jiaotong University (CN)
National Natural Science Foundation of China
Openalex Percentile: Top 65%
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.